- Home
- CGEM vs ELVR Comparison
CGEM vs ELVR Comparison
Compare CGEM & ELVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGEM | ELVR |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Mining & Quarrying of Nonmetallic Minerals (No Fuels) |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.4M | 1.1B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CGEM | ELVR |
|---|---|---|
| Price | $12.92 | $27.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $33.45 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 43.4K |
| Earning Date | 11-05-2026 | 10-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $93.80 |
| Revenue Next Year | $280.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.73 | $23.70 |
| 52 Week High | $23.19 | $102.80 |
Technical Indicators
Market Signals| Indicator | CGEM | ELVR |
|---|---|---|
| Relative Strength Index (RSI) | 27.50 | 12.80 |
| Support Level | $11.87 | N/A |
| Resistance Level | $13.21 | $69.79 |
| Average True Range (ATR) | 0.91 | 1.35 |
| MACD | -0.14 | -0.43 |
| Stochastic Oscillator | 0.64 | 1.59 |
Price Performance
Historical ComparisonAbout CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
About ELVR Sayona Mining Limited American Depository Shares
Elevra Lithium Ltd is a mineral exploration and development company. The principal activity of the company is lithium mining and processing at North American Lithium(NAL) and ongoing identification, evaluation and development of its world-wide portfolio of mineral exploration assets, predominantly focusing on lithium. Its segments are North American Lithium, and All other operations. Majority of revenue comes from North American Lithium. It has presence in China, and USA. Majority of revenue comes from China.